- Home
- BDSX
BDSX
Biodesix Inc.
as 10-21-2024 4:00pm EST
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | LOUISVILLE |
| Market Cap: | 245.3M | IPO Year: | 2020 |
| Target Price: | $3.08 | AVG Volume (30 days): | 118.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.15 - $2.21 | Next Earning Date: | 11-01-2024 |
| Revenue: | $60,902,000 | Revenue Growth: | 46.25% |
| Revenue Growth (this year): | 48.06% | Revenue Growth (next year): | 29.97% |
Stock Insider Trading Activity of Biodesix Inc. (BDSX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Vazquez Chris | BDSX | Chief Accounting Officer | Aug 8 '24 | Sell | $1.59 | 209 | $333.04 | 11,242 | |
| Pestano Gary Anthony | BDSX | Chief Development Officer | Aug 8 '24 | Sell | $1.59 | 431 | $686.80 | 126,187 | |
| Cowie Robin Harper | BDSX | CFO, Sec'y & Treasurer | Aug 8 '24 | Sell | $1.59 | 975 | $1,553.67 | 191,151 | |
| Hutton Scott | BDSX | President & CEO | Aug 8 '24 | Sell | $1.59 | 3,744 | $5,966.12 | 519,331 |
Latest Biodesix Inc. News
BDSX Breaking Stock News: Dive into BDSX Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024
Business Wire
15 days ago
Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Business Wire
2 months ago
Biodesix to Present at Two Investor Conferences in September
Simply Wall St.
2 months ago
Biodesix Second Quarter 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
2 months ago
Q2 2024 Biodesix Inc Earnings Call
Zacks
2 months ago
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
Business Wire
2 months ago
Biodesix Announces Second Quarter 2024 Results and Highlights
Business Wire
3 months ago
Biodesix to Present at Canaccord Genuity’s 44th Annual Growth Conference
Compare BDSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDSX Biodesix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.